Comparative sequencing of the proneurotensin gene and association studies in schizophrenia

Molecular Psychiatry

Volumn 5, Issue 2, 2000, Pages 208-212

  Austin, J ^a   Hoogendoorn, B ^a   Buckland, P ^a   Speight, G ^a   Cardno, A ^a   Bowen, T ^a   Williams, N ^a   Spurlock, G ^a   Sanders, R ^a   Jones, L ^a   Murphy, K ^a   McCarthy, G ^a   McGuffin, P ^a   Owen, M J ^a   O'Donovan, M C ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Gene; Mutation; Polymorphism; Proneurotensin; Schizophrenia

Indexed keywords

NEUROTENSIN;

ARTICLE; CASE CONTROL STUDY; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA;

EID: 0034011878     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000693     Document Type: Article

References (27)

1. 1 Mai J, Triepel KJ, Metz J. Neurotensin in the human brain. Neuroscience 1987; 22: 499-524.
2. 2 Quirion R. Interactions between neurotensin and dopamine in the brain: an overview. Peptides 1983; 4: 609-615.
3. 3 Nemeroff CB. The interaction of neurotensin with dopaminergic pathways in the central nervous system: basic neurobiology and implications for the pathogenesis and treatment of schizophrenia. Psychoneuroendocrinology 1986; 11: 15-37.
4. 4 Bean AJ, Dagerlind A, Hokfelt T, Dobner PR. Cloning of human neurotensin/neuromedin N genomic sequences and expression in the ventral mesencephalon of schizophrenics and age/sex matched controls. Neuroscience 1992; 50: 259-268.
5. 5 Lambert PD, Gross R, Nemeroff CB, Kilts CD. Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system. Ann New York Acad Sci 1995; 757: 377-389.
6. 6 Sotty F, Souliere F, Brun P, Chouvet G, Steinberg R, Soubrie P et al. Differential effects of neurotensin on dopamine, release in the caudal and rostral nucleus accumbens: a combined electrochemical and electrophysiological study. Neuroscience 1998; 85: 1173-1182.
7. 7 Liu Y, Hillefors-Berglund M, Von Euler G. Modulation of dopamine D3 receptor binding by N-ethylmaleimide and neurotensin. Brain Res 1994; 643: 343-348.
8. 8 Azzi M, Betancur C, Sillaber I, Spanagel R, Rostene W, Berod A. Repeated administration of the neurotensin receptor antagonist SR 48692 differentially regulates mesocortical and mesolimbic dopaminergic systems. J Neurochem 1998; 71: 1158-1167.
9. 9 Kasckow J, Nemeroff CB. The neurobiology of neurotensin-focus on neurotensin-dopamine interactions, Regul Peptides 1991; 36: 153-164.
10. 10 Nemeroff CB, Levant B, Myers B, Bissette G. Neurotensin, antipsychotic drugs and schizophrenia. Ann New York Acad Sci 1992; 668: 146-156.
11. 11 Nemeroff CB. Neurotensin, perchance an endogenous neuroleptic? Biol Psychiatry 1980; 15: 283-302.
12. 12 Sharma RP, Janicak PJ, Bissette G, Nemeroff CB. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Am J Psychiatry 1997; 154: 1019-1021.
13. 13 Garver DL, Bissette G, Yao JK, Nemeroff CB. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Am J Psychiatry 1991; 148; 484-488.
14. 14 Underhill PA, Jin L, Lin AA, Mehdi SQ, Jenkins T, Vollrath D et al. Detection of numerous Y chromosome biallelic polymorphisms by denaturing high performance liquid chromatography. Genome Res 1997; 7: 996-1005.
15. 15 Hoogendoorn B, Owen M, Oefner PJ, Williams N, Austin J, O'Donovan MC. Genotyping single nucleotide polymorphisms by primer extension and high performance liquid chromatography. Hum Genet 1999; 104: 89-93.
16. 16 Marondel I, Renault B, Lieman J, Ward D, Kucherlapati R. Physical mapping of the human neurotensin gene (NTS) between markers D12S1444 and D12S81 on chromosome 12q21. Genomics 1996; 38: 243-245.
17. 17 Sobell JL, Heston LL, Sommer SS. Delineation of genetic predisposition to multifactorial disease: a general approach on the threshold of feasibility. Genomics 1992; 12: 1-6.
18. 18 O'Donovan MC, Oefner PJ, Roberts SC, Austin J, Hoogendoorn B, Guy C et al. Blind analysis of denaturing high performance liquid Chromatography as a tool for mutation detection. Genomics 1998; 52: 44-49.
19. 19 Jones A, Austin J, Hansen N, Hoogendoorn B, Oefner PJ, Cheadle JP et al. Optimal temperature selection for mutation detection by denaturing high performance liquid chromatography and comparison to SSCP and heteroduplex analysis. Clin Chem 1999; 45: 1133-1140.
20. 20 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn). American Psychiatric Association: Washington DC, 1994.
21. 21 McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 1991; 48: 764-770.
22. 22 Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R et al. SCAN: Schedules for clinical assessment in neuropsychiatry. Arch Gen Psychiatry 1990; 47: 589-593.
23. 23 Wing JK, Cooper JE, Sarlorius N. Measurement and Classification of Psychiatric Symptoms. Cambridge University Press: Cambridge, 1972.
24. 24 Owen MJ, Holmans P, McGuffin P. Association study in psychiatric genetics. Mol Psychiatry 1997; 2: 270-273.
25. 25 Krawczak M, Konecki DS, Schmidtke J, Dück M, Engel W, Nützenadel W et al. Allelic association of the cystic fibrosis locus and two DNA markers, XV2c and KM19, in German families. Hum Genet 1998; 80: 78-80.
26. 26 Lewontin RC. The interaction of selection and linkage. I. General considerations; heterotic models. Genetics 1964; 49: 49-67
27. 27 Devlin B, Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 1995; 29: 311-322.